Navigation Links
Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Date:9/19/2007

Novel Antibiotic Candidate Rapidly Bactericidal Against Both Cultures and

Spores of the Anaerobic Bacterium Using Multiple in Vitro Methods

CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released data from two studies comparing the in vitro activity of its lead antibiotic drug candidate, oritavancin, to that of other antibiotics against Clostridium difficile bacteria. Results are being presented today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Chicago, IL.

C. difficile are anaerobic, gram-positive, spore-forming bacteria that are a major cause of morbidity in the hospitalized elderly. C. difficile infection is associated with many diseases, the most significant of which are uncomplicated diarrhea and pseudomembranous colitis, or severe infection of the colon. Often, after normal gut flora are eradicated by the use of antibiotics, it is postulated that C. difficile spores refractory to current antimicrobial therapies persist, causing recurrent infections. The U.S. Centers for Disease Control and Prevention (CDC) reports that each year nearly 10 percent of all hospitalized patients, or two million patients, contract C. difficile infections during their stay.

In the first study, presented as a poster entitled "In Vitro Susceptibility of Genotypically Distinct Clostridium difficile Strains to Oritavancin," researchers tested the activity of oritavancin versus the standards of care, metronidazole and vancomycin, against 33 genotypically distinct strains of C. difficile bacteria. Overall, in this study, oritavancin was more active than either metronidazole or vancomycin, and oritavancin was more active than vancomycin against 94% of the C. difficile strains tested by the broth macrodilution method.

In the second study, accepted as a late-breaker poster presentation entitled "Activity of Metronidazole, Vancomycin and Oritavancin Against Epidemic C
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Concord Medical Services Holdings Limited ("Concord ... a leading specialty hospital management solution provider and ... diagnostic imaging centers in China ... agreement under which Concord Medical Services (International) Pte ... agreed to acquire the Fortis Surgical Hospital from ...
(Date:3/26/2015)... 2015 "Whether it,s our family, our friends, ... In a single sentence, Dr. Anthony Coyle ... Pfizer,s Centers for Therapeutic Innovation (CTI), sums ... at America,s biopharmaceutical companies. CTI,s unique ... patient foundations and the National Institutes of Health (NIH) ...
(Date:3/26/2015)... NEW YORK , March 26, 2015 /PRNewswire-USNewswire/ ... on the average American consumer. However, a new ... treating various ailments from the common cold to ... The research, conducted by the Private ... focused on over-the-counter healthcare products, including those essential ...
Breaking Medicine Technology:Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Consumers can keep over-the-counter medicine affordable by using store brands 2
... 11, 2007 - Neose Technologies,Inc. (Nasdaq ... presentations,were presented with its collaborative partner, ... Factor VIIa at the XXIst,Congress of ... Haemostasis,in Geneva, Switzerland. The data presented ...
... 2007 /PRNewswire-FirstCall/ -- On Wednesday,July 11, 2007, ... European Time members of Cell Therapeutics, Inc.'s ... to discuss today's,announcement of the interim results ... to CPOP-R, in which pixantrone is substituted ...
Cached Medicine Technology:Neose Announces Presentation of Positive Preclinical Data on,GlycoPEGylated Factor VIIa at the XXI Congress of the International,Society on Thrombosis and Haemostasis 2Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results 2
(Date:3/27/2015)... 2015 The report “CountryFocus Healthcare, ... essential source of information on and analysis of ... Germany’s increasingly elderly population and its associated disease ... In 2013, the elderly accounted for 27.1% of ... Annual Growth Rate (CAGR) of 1.2% to 29.5% ...
(Date:3/27/2015)... 27, 2015 On March 19, ... former Detroit Lions wide receiver Herman Moore, hosted ... presentation on substance abuse, treatment options and the ... attended were pastors, ministers and bishops from local ... distinguished guests. , “Our ‘Fighting Addiction Together’ luncheon ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 SMI ... today announced it has launched the SM1120 MEMS based ... market. The microsensor profile at only 220um x ... maneuverability to reach challenging locations. With industry leading ... hour, the SM1120 provides a broad operating pressure range ...
(Date:3/27/2015)... March 27, 2015 Trail mix is the ... workout, on weekend hikes and during the game! It’s portable, ... Natural is proud to introduce a new line of specialty ... Deliciously rich and flavorful selections packed with nutritious, 100% all ... fruit and grains that add protein and fiber to your ...
(Date:3/27/2015)... Jersey (PRWEB) March 27, 2015 Airy ... has released the official music video for her debut ... , Combining live-action and abstract styling effects, the ... be viewed on YouTube, Vimeo, and assorted outlets. It ... the development of an expanding full-scale marketing strategy. The ...
Breaking Medicine News(10 mins):Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:LiveToBeSober.org Hosts Conference on Substance Abuse Treatment and Recovery at Ford Field 2Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2
... can increase the risk of an acute attack of pancreatitis, but ... according to a study published online by BJS, the British ... in Sweden followed 84,601 people from 46 to 84 years of ... median of ten years. During that time 513 developed acute pancreatitis. ...
... , WEDNESDAY, Aug. 3 (HealthDay News) -- First they spread ... newly identified bacterium are infecting residents of the midwestern United ... will likely appear in other areas of the country. ... fatigue, has been identified in 25 people in Minnesota ...
... ITHACA, N.Y. U.S. physicians spend nearly $61,000 more ... related to health insurance, according to a new study ... Toronto. The study, published in the August issue ... per-physician costs in the U.S. averaged $82,975 annually, while ...
... (HealthDay News) -- Pregnant women who take ongoing, high doses ... increased risk of having babies with birth defects, the U.S. ... used to treat yeast infections of the vagina, mouth, throat, ... caused by a certain type of fungus and to prevent ...
... Jenifer Goodwin HealthDay Reporter , WEDNESDAY, Aug. ... for certain markers in the blood called "autoantibodies" is ... The blood test correctly detected Alzheimer,s disease in people ... percent accuracy, according to the researchers. The test could ...
... The Gerontological Society of America (GSA) the nation,s largest ... the National Center for Creative Aging (NCCA) have chosen Barry ... the 2011 recipient of the Gene D. Cohen Research Award ... the seminal work of Gene Cohen, MD, whose research in ...
Cached Medicine News:Health News:Drinking just 1 measure of spirits increases the risk of acute pancreatitis 2Health News:New Tick-Borne Illness Infects Midwesterners 2Health News:New Tick-Borne Illness Infects Midwesterners 3Health News:US physicians spend nearly 4 times more on health insurance costs than Canadian counterparts 2Health News:High Dose of Yeast Infection Drug Linked to Birth Defects, FDA Says 2Health News:Another Blood Test for Alzheimer's Shows Promise 2Health News:Another Blood Test for Alzheimer's Shows Promise 3Health News:Another Blood Test for Alzheimer's Shows Promise 4Health News:Bittman to receive 2011 Gene D. Cohen Award 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: